An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link
暂无分享,去创建一个
Andrew I. Bell | Josef Mautner | Georg W. Bornkamm | M. Rowe | G. Bornkamm | A. Rickinson | A. Leese | J. Mautner | G. Kelly | Martin Rowe | Gemma L. Kelly | Julianna Stylianou | Alan B. Rickinson | A. Bell | Heather M. Long | Wendy A. Thomas | Alison Leese | Julianna Stylianou | H. Long | W. Thomas
[1] J. Sample,et al. Epstein-Barr Virus Small RNAs Potentiate Tumorigenicity of Burkitt Lymphoma Cells Independently of an Effect on Apoptosis , 2000, Journal of Virology.
[2] J. Strominger,et al. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[3] A. Rickinson,et al. CD4+ T-Cell Responses to Epstein-Barr Virus (EBV) Latent-Cycle Antigens and the Recognition of EBV-Transformed Lymphoblastoid Cell Lines , 2005, Journal of Virology.
[4] M. Rowe,et al. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[5] R. Palmiter,et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.
[6] P. L. Deininger,et al. DNA sequence and expression of the B95-8 Epstein—Barr virus genome , 1984, Nature.
[7] K. Takada,et al. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV , 1994, Journal of virology.
[8] E. Kieff,et al. Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[9] L. Young,et al. Differences in B cell growth phenotype reflect novel patterns of Epstein‐Barr virus latent gene expression in Burkitt's lymphoma cells. , 1987, The EMBO journal.
[10] K. Takada,et al. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes , 1989, Journal of virology.
[11] J. Sample,et al. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein , 1996, Journal of virology.
[12] D. Kerr,et al. Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells , 2002, Cell Death and Differentiation.
[13] M. Bonneville,et al. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. , 2004, Blood.
[14] M. Perricaudet,et al. Epstein-Barr virus mRNAs produced by alternative splicing. , 1986, Nucleic acids research.
[15] W. Hammerschmidt,et al. Epstein-Barr Virus Nuclear Antigen 2 (EBNA2) Gene Deletion Is Consistently Linked with EBNA3A, -3B, and -3C Expression in Burkitt's Lymphoma Cells and with Increased Resistance to Apoptosis , 2005, Journal of Virology.
[16] Anton J. Enright,et al. Identification of Virus-Encoded MicroRNAs , 2004, Science.
[17] A. Rickinson,et al. Three restricted forms of Epstein–Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells , 2006, Proceedings of the National Academy of Sciences.
[18] E. White,et al. Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. , 2002, Genes & development.
[19] S. Tangye,et al. Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients. , 2008, Blood.
[20] P. Bouillet,et al. Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[21] E. Hui,et al. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. , 2006, The Journal of general virology.
[22] D. Kwong,et al. An Epstein-Barr virus–encoded microRNA targets PUMA to promote host cell survival , 2008, The Journal of experimental medicine.
[23] H. Bujard,et al. Stringent doxycycline-dependent control of gene activities using an episomal one-vector system , 2005, Nucleic Acids Research.
[24] Chen-feng Qi,et al. Burkitt Lymphoma in the Mouse , 2000, The Journal of experimental medicine.
[25] B. Kempkes,et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[26] J. Strominger,et al. Isolation and characterization of cDNA clones corresponding to transcripts from the BamHI H and F regions of the Epstein-Barr virus genome , 1987, Journal of virology.
[27] L. Xing,et al. Epstein-Barr Virus BHRF1 Micro- and Stable RNAs during Latency III and after Induction of Replication , 2007, Journal of Virology.
[28] K. Takada,et al. Epstein-Barr Virus Contributes to the Malignant Phenotype and to Apoptosis Resistance in Burkitt’s Lymphoma Cell Line Akata , 1998, Journal of Virology.
[29] A. Nanbo,et al. Replacement of the Epstein-Barr Virus Plasmid with the EBER Plasmid in Burkitt's Lymphoma Cells , 2001, Journal of Virology.
[30] A. Rickinson,et al. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. , 2007, Hematology. American Society of Hematology. Education Program.
[31] P. Farrell,et al. Epstein–Barr virus and Burkitt lymphoma , 2007, Journal of Clinical Pathology.
[32] S. Lowe,et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants , 2005, Nature.
[33] Robert E. White,et al. Two Epstein–Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma , 2008, Oncogene.
[34] I. Magrath. The pathogenesis of Burkitt's lymphoma. , 1990, Advances in cancer research.
[35] E. Kieff,et al. Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. , 1987, Virology.
[36] M. Rowe,et al. Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody. , 1994, The Journal of general virology.
[37] Y. Kawaguchi,et al. Truncated Form of the Epstein-Barr Virus Protein EBNA-LP Protects against Caspase-Dependent Apoptosis by Inhibiting Protein Phosphatase 2A , 2007, Journal of Virology.
[38] A. Rickinson,et al. Epstein–Barr virus–associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2 , 2002, Nature Medicine.
[39] T. Frey,et al. Nucleic acid dyes for detection of apoptosis in live cells. , 1995, Cytometry.
[40] B. Sugden,et al. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[41] David L. Vaux,et al. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.
[42] S. Maruo,et al. Oncogenic Role of Epstein-Barr Virus-Encoded RNAs in Burkitt’s Lymphoma Cell Line Akata , 1999, Journal of Virology.
[43] A. Rickinson,et al. Methylation Status of theEpstein-Barr Virus (EBV) BamHI W Latent Cycle Promoter and Promoter Activity: Analysis with Novel EBV-Positive Burkitt and LymphoblastoidCell Lines , 2006, Journal of Virology.
[44] W. Hammerschmidt,et al. The Epstein–Barr virus lytic program is controlled by the co‐operative functions of two transactivators , 2000, The EMBO journal.
[45] J. Strominger,et al. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[46] Alexandra Schäfer,et al. Epstein–Barr Virus MicroRNAs Are Evolutionarily Conserved and Differentially Expressed , 2006, PLoS pathogens.
[47] J. Pevsner,et al. Viral Bcl-2 homologs and their role in virus replication and associated diseases. , 2004, Biochimica et biophysica acta.
[48] J. Strominger,et al. Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[49] L. T. Krug,et al. Variable Methylation of the Epstein-Barr Virus Wp EBNA Gene Promoter in B-Lymphoblastoid Cell Lines , 2004, Journal of Virology.
[50] A. Rickinson,et al. Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones , 1991, Journal of virology.
[51] W. Hammerschmidt,et al. Epstein-Barr Virus Provides a New Paradigm: A Requirement for the Immediate Inhibition of Apoptosis , 2005, PLoS biology.
[52] G. Williams,et al. The Epstein-Barr virus gene BHRF1, a homologue of the cellular oncogene Bcl-2, inhibits apoptosis induced by gamma radiation and chemotherapeutic drugs. , 1996, Advances in experimental medicine and biology.
[53] S. Kawanishi,et al. Epstein-Barr virus BHRF1 functions downstream of Bid cleavage and upstream of mitochondrial dysfunction to inhibit TRAIL-induced apoptosis in BJAB cells. , 2002, Biochemical and biophysical research communications.
[54] Chen-feng Qi,et al. Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells. , 2005, Blood.
[55] P. Rivailler,et al. Complete Genomic Sequence of an Epstein-Barr Virus-Related Herpesvirus Naturally Infecting a New World Primate: a Defining Point in the Evolution of Oncogenic Lymphocryptoviruses , 2002, Journal of Virology.
[56] D. Markovitz,et al. Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia. , 1995, The Journal of infectious diseases.
[57] L. Resnick,et al. The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression , 1994, Journal of virology.